Search

Edwards Lifesciences Corp

Fechado

SetorSaúde

85.64 2.51

Visão Geral

Variação de preço das ações

24h

Atual

Mín

82.71

Máximo

85.47

Indicadores-chave

By Trading Economics

Rendimento

290M

381M

Vendas

92M

1.7B

P/E

Médio do Setor

49.429

64.641

EPS

0.78

Margem de lucro

23.092

Funcionários

16,000

EBITDA

20M

520M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+22.94% upside

Dividendos

By Acuity

Próximos Ganhos

29 de out. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-1.1B

48B

Abertura anterior

83.13

Fecho anterior

85.64

Sentimento de Notícias

By Acuity

55%

45%

253 / 340 Ranking em Healthcare

Edwards Lifesciences Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de jul. de 2026, 18:46 UTC

News

UBS analyst Danielle Antalffy initiated coverage on Edwards Lifesciences with a Buy rating and $110 price target, boosting shares modestly higher today.

27 de jul. de 2026, 19:41 UTC

Social Media
News

Edwards Lifesciences shares rise as TAVR revenue hits $35 million, driven by a 10.5% increase in U.S. sales, surpassing expectations.

24 de jul. de 2026, 18:41 UTC

News

Edwards Lifesciences Corp is trading lower today despite positive analyst ratings. The stock pulled back from an earlier session high and has declined since Thursday's close.

23 de jul. de 2026, 23:41 UTC

News
Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

22 de jul. de 2026, 18:46 UTC

Edwards Lifesciences shares are trading higher during Wednesday's session, showing slight gains despite recent declines in the broader market.

21 de jul. de 2026, 21:02 UTC

Edwards Lifesciences Corp shares are lower in after-market hours, continuing a trend of three consecutive sessions below the 20-day moving average.

20 de jul. de 2026, 19:56 UTC

News

Edwards Lifesciences shares are lower as regulatory challenges arise from a $12 million FTC penalty and new restrictions on valve replacement agreements.

Comparação entre Pares

Variação de preço

Edwards Lifesciences Corp Previsão

Preço-alvo

By TipRanks

22.94% parte superior

Previsão para 12 meses

Média 102.88 USD  22.94%

Máximo 110 USD

Mínimo 85 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Edwards Lifesciences Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

19 ratings

16

Comprar

3

Manter

0

Vender

Sentimento

By Acuity

253 / 340 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
help-icon Live chat